GlassScriptPhysician profile
Krysten Gibbs
NPI 1154007565
$5,580.63
in general payments reported to CMS, 2019-2025
43 companies · $3,061 in 2025
The $3,061 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,519 · 2025: $3,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,580.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $551.20 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $389.79 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Gilead Sciences, INC. | $311.26 | 2024-2025 | Trodelvy |
| Incyte Corporation | $301.28 | 2024-2025 | Monjuvi, Jakafi, Zynyz |
| Celgene Corporation | $293.80 | 2024-2025 | Reblozyl, Pomalyst |
| Bayer Healthcare Pharmaceuticals INC. | $269.82 | 2024-2025 | |
| Pfizer INC. | $255.73 | 2024-2025 | |
| Janssen Biotech, INC. | $254.69 | 2024-2025 | Rybrevant, Darzalex, Tecvayli |
| Daiichi Sankyo INC. | $231.53 | 2024-2025 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $223.39 | 2024-2025 | Enhertu, Imfinzi, Calquence |
| Abbvie INC. | $200.88 | 2024-2025 | |
| Eisai INC. | $166.85 | 2024-2025 | |
| Astellas Pharma US INC | $157.51 | 2024-2025 | Padcev, Vyloy, Xtandi |
| Lilly USA, LLC | $157.49 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Glaxosmithkline, LLC. | $154.41 | 2024-2025 | Ojjaara, Blenrep |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $145.40 | 2024-2025 | Fruzaqla, Alunbrig, Hyqvia |
| Regeneron Healthcare Solutions, INC. | $127.70 | 2024-2025 | Libtayo |
| Sobi, INC | $97.96 | 2024-2025 | |
| Legend Biotech USA INC. | $96.14 | 2025 | Carvykti |
| Array Biopharma INC | $95.92 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| E.R. Squibb & Sons, L.L.C. | $95.41 | 2024-2025 | Opdivo, Krazati |
| Dendreon Pharmaceuticals LLC | $94.75 | 2025 | Provenge |
| Alexion Pharmaceuticals, INC. | $92.81 | 2024-2025 | Ultomiris |
| Pharmacosmos Therapeutics INC. | $91.00 | 2024-2025 | Monoferric, Cosela |
| Kyowa Kirin, INC. | $87.29 | 2025 | |
| Emd Serono, INC. | $72.87 | 2024-2025 | |
| Taiho Oncology, INC. | $71.93 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $64.49 | 2024-2025 | Onivyde, Somatuline Depot |
| Atricure, INC. | $57.79 | 2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Stemline Therapeutics INC. | $55.25 | 2024-2025 | Orserdu |
| Sumitomo Pharma America, INC. | $38.86 | 2024-2025 | Orgovyx |
| Exelixis INC. | $35.59 | 2024 | Cabometyx |
| Jazz Pharmaceuticals INC. | $35.07 | 2024-2025 | |
| Genzyme Corporation | $30.29 | 2025 | |
| Kite Pharma, INC. | $29.76 | 2025 | Yescarta |
| Adaptive Biotechnologies Corporation | $26.82 | 2024 | Clonoseq |
| Myriad Genetic Laboratories, INC. | $21.10 | 2024 | Myrisk |
| Puma Biotechnology, INC. | $19.54 | 2025 | |
| Aveo Pharmaceuticals, INC. | $18.59 | 2024 | |
| Tersera Therapeutics LLC | $16.38 | 2025 | Zoladex |
| Azurity Pharmaceuticals, INC. | $14.31 | 2025 | Danziten |
| Genentech USA, INC. | $14.12 | 2024 | Alecensa, Tecentriq, Polivy |
| Genmab U.S., INC. | $13.86 | 2025 | Epkinly |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krysten Gibbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.